Lenvatinib shows potential in advanced liver cancer

Lenvatinib may become a potential therapeutic option for patients with advanced hepatocellular carcinoma (HCC), the results of phase I/II clinical trial suggest.

Hepatocellular carcinoma: potential treatment identified (photo: SPL)
Hepatocellular carcinoma: potential treatment identified (photo: SPL)

The findings were presented at the 2012 meeting of the European Society of Medical Oncology in Vienna this month.

Lenvatinib, an orally active inhibitor of multiple receptor tyrosine kinases (RTKs) involved in angiogenesis and tumour proliferation, is being investigated for the treatment of recurrent glioblastoma and in combination with everolimus in metastatic renal carcinoma.

The scope of the phase I/II clinical trial was to establish the safety and efficacy of lenvatinib in patients with advanced HCC.

Forty-six patients were enrolled in the trial; they may have had prior treatment for their HCC including sorafenib. The starting dose of lenvatinib was 12mg once daily in 28 days cycles until disease progression or progression of unmanageable toxicities.

The researchers observed that 76% patients required dose adjustments for the management of toxicities (hypertension, palmo-plantar erythrodysaesthesia syndrome, anorexia, proteinuria, fatigue and thrombocytopenia).

They concluded that, although in this study there were no new toxicities associated with TKI class, a weight-based starting dose of 8mg once daily for patients weighing under 60kg may be needed to minimise toxicity while maintaining the 12mg once daily for patients weighing over 60kg.

The median time to progression (TTP) is 7.49 months (95% CI:5.45-9.43) and media overall survival is 13.9 months (95% CI:11.8-).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Almost 4,000 GPs rejoin GMC register as COVID-19 deaths surge

Almost 4,000 GPs rejoin GMC register as COVID-19 deaths surge

Around 3,800 GPs have rejoined the medical register barely a week after the government...

Prime minister Boris Johnson and health secretary Matt Hancock infected with COVID-19

Prime minister Boris Johnson and health secretary Matt Hancock infected with COVID-19

Prime minister Boris Johnson and health and social care secretary Matt Hancock are...

'Lovely' Essex GP feared to be first UK doctor to die from COVID-19

'Lovely' Essex GP feared to be first UK doctor to die from COVID-19

An Essex GP is feared to have become the first UK doctor to die after being infected...

How PCNs are adapting to the COVID-19 pandemic

How PCNs are adapting to the COVID-19 pandemic

Primary care networks (PCNs) are hosting virtual training sessions and re-writing...

Guidance updated for pregnant healthcare staff in coronavirus outbreak

Guidance updated for pregnant healthcare staff in coronavirus outbreak

All GPs who are pregnant should have the choice to stop work in patient-facing roles...

More than 550 GPs sign up within 24 hours to support NHS111

More than 550 GPs sign up within 24 hours to support NHS111

More than 550 GPs have signed up within 24 hours to take calls for NHS 111 as the...